

A Scandinavian randomised-controlled trial of the effects of antithrombotic treatment (antiplatelet or anticoagulant drugs) for prevention of ischaemic events in patients with prior intracerebral haemorrhage

STATICH-Antiplatelets
(for patients with **vascular disease** and indication for **antiplatelet drugs**)


Inclusion criteria:

- Spontaneous, primary intracerebral haemorrhage minimum 1 day ago (no preceding traumatic head injury, no underlying structural cause)
- **Vascular disease and indication for antiplatelet drug**
- Cerebral MRI (and/or CT)
- Informed consent (or assent by relative, Norway only)
- Age ≥ 18 years

Exclusion criteria:

- **Clear indication for antiplatelet drug** (e.g. recent coronary artery stenting)
- Clear contraindication for antiplatelet drugs
- Pregnant or breastfeeding, or no contraceptive methods (if fertile age)
- Malignancy with life expectancy < 2 years

Randomisation 1:1



STATICH-Anticoagulants
(for patients with **atrial fibrillation** and indication for **anticoagulant drugs**)


Inclusion criteria:

- Spontaneous, primary intracerebral haemorrhage minimum 1 day ago (no preceding traumatic head injury, no underlying structural cause)
- **Atrial fibrillation and indication for anticoagulant drug**
- Cerebral MRI (and/or CT)
- Informed consent (or assent by relative, Norway only)
- Age ≥ 18 years

Exclusion criteria:

- **Clear indication for anticoagulant drug** (e.g. prosthetic metallic heart valve)
- Clear contraindication for anticoagulant drugs
- Pregnant or breastfeeding, or no contraceptive methods (if fertile age)
- Malignancy with life expectancy < 2 years

Randomisation 1:1



Recruitment procedure

1. Ask for informed consent (form can be found in Investigator Site File or on www.statich.no).
2. Perform Cerebral MRI with SWI before randomisation.
3. Fill in CRF (can be found in Investigator Site File or on www.statich.no).
4. Randomisation: www.statich.no (log in).
5. If allocated antithrombotic treatment: Prescribe antiplatelet or anticoagulant drug at your own choice.
6. Fill in the "Patient Contact Details" (can be found on the last page of the randomisation system, or on www.statich.no) and send it to the national co-ordinating centre. We will contact the patient within 1 month.
7. Please send a CD with CT and MRI scans (including Scan Transfer Form) to STATICH Co-ordinating Centre at Oslo University Hospital.

Questions? Please contact **trial manager Kristin Larsen** at +47 98671138 (office hours) or +47 22119911 (24/7), or k.t.larsen@medisin.uio.no, or the national co-ordinators:

Johanna Pennlert johanna.pennlert@umu.se Tel.: +46 090-785 1719	Eva-Lotta Glader eva-lotta.glader@umu.se Tel.: +46 090-785 3186	Christina Kruuse christina.kruuse@regionh.dk Tel.: +45 38681233	Eivind Berge eivind.berge@medisin.uio.no Tel.: +47 22119100
--	--	--	--